Cost-Effectiveness of Mirabegron Compared with Tolterodine ER 4mg for the Treatment of Patients with Overactive Bladder in the United Kingdom: Results from a Trial-Based Model
HomePublicationsCost-Effectiveness of Mirabegron Compared with Tolterodine ER 4mg for the Treatment of Patients with Overactive Bladder in the United Kingdom: Results from a Trial-Based Model
Cost-Effectiveness of Mirabegron Compared with Tolterodine ER 4mg for the Treatment of Patients with Overactive Bladder in the United Kingdom: Results from a Trial-Based Model
2013 Value in health
Aballea, S. | Maman, K. | Desroziers, K. | Nazir, J. | Odeyemi, I.A.O. | Hakimi, Z. | Garnham, A. | Toumi, M. |
Volume: 16,
Issue: 7,
Pages: A633,
m,
Mirabegron is a first-in-class beta-3 adrenoceptor agonist for the treatment of overactive bladder (OAB) that demonstrated superior efficacy compared to placebo in OAB. The cost-effectiveness of mirabegron 50 mg (MGN) was assessed in comparison with tolterodine ER 4 mg (TOL) in the UK.
